PMID- 38178560
OWN - NLM
STAT- MEDLINE
DCOM- 20240408
LR  - 20240408
IS  - 1098-1128 (Electronic)
IS  - 0198-6325 (Linking)
VI  - 44
IP  - 3
DP  - 2024 May
TI  - CXCR4/CXCL12 axis: "old" pathway as "novel" target for anti-inflammatory drug 
      discovery.
PG  - 1189-1220
LID - 10.1002/med.22011 [doi]
AB  - Inflammation is the body's defense response to exogenous or endogenous stimuli, 
      involving complex regulatory mechanisms. Discovering anti-inflammatory drugs with 
      both effectiveness and long-term use safety is still the direction of 
      researchers' efforts. The inflammatory pathway was initially identified to be 
      involved in tumor metastasis and HIV infection. However, research in recent years 
      has proved that the CXC chemokine receptor type 4 (CXCR4)/CXC motif chemokine 
      ligand 12 (CXCL12) axis plays a critical role in the upstream of the inflammatory 
      pathway due to its chemotaxis to inflammatory cells. Blocking the chemotaxis of 
      inflammatory cells by CXCL12 at the inflammatory site may block and alleviate the 
      inflammatory response. Therefore, developing CXCR4 antagonists has become a novel 
      strategy for anti-inflammatory therapy. This review aimed to systematically 
      summarize and analyze the mechanisms of action of the CXCR4/CXCL12 axis in more 
      than 20 inflammatory diseases, highlighting its crucial role in inflammation. 
      Additionally, the anti-inflammatory activities of CXCR4 antagonists were 
      discussed. The findings might help generate new perspectives for developing 
      anti-inflammatory drugs targeting the CXCR4/CXCL12 axis.
CI  - (c) 2024 Wiley Periodicals LLC.
FAU - Lu, Liuxin
AU  - Lu L
AD  - Department of Medicinal Chemistry, School of Pharmacy, Hangzhou Normal 
      University, Hangzhou, Zhejiang, China.
AD  - Key Laboratory of Elemene Class Anti-tumor Chinese Medicines, Engineering 
      Laboratory of Development and Application of Traditional Chinese Medicines, 
      Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang 
      Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.
FAU - Li, Junjie
AU  - Li J
AD  - Department of Medicinal Chemistry, School of Pharmacy, Hangzhou Normal 
      University, Hangzhou, Zhejiang, China.
AD  - Key Laboratory of Elemene Class Anti-tumor Chinese Medicines, Engineering 
      Laboratory of Development and Application of Traditional Chinese Medicines, 
      Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang 
      Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.
FAU - Jiang, Xiaoying
AU  - Jiang X
AD  - Department of Medicinal Chemistry, School of Pharmacy, Hangzhou Normal 
      University, Hangzhou, Zhejiang, China.
AD  - Key Laboratory of Elemene Class Anti-tumor Chinese Medicines, Engineering 
      Laboratory of Development and Application of Traditional Chinese Medicines, 
      Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang 
      Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.
FAU - Bai, Renren
AU  - Bai R
AUID- ORCID: 0000-0002-3511-5794
AD  - Department of Medicinal Chemistry, School of Pharmacy, Hangzhou Normal 
      University, Hangzhou, Zhejiang, China.
AD  - Key Laboratory of Elemene Class Anti-tumor Chinese Medicines, Engineering 
      Laboratory of Development and Application of Traditional Chinese Medicines, 
      Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang 
      Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.
LA  - eng
GR  - 82304284/National Natural Science Foundation of China/
GR  - 2021QDL026/Scientific Research Foundation for Scholars of HZNU/
GR  - KYQD-2023-175/Scientific Research Foundation for Scholars of HZNU/
PT  - Journal Article
PT  - Review
DEP - 20240104
PL  - United States
TA  - Med Res Rev
JT  - Medicinal research reviews
JID - 8103150
RN  - 0 (Receptors, CXCR4)
RN  - 0 (Chemokine CXCL12)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (CXCL12 protein, human)
RN  - 0 (CXCR4 protein, human)
SB  - IM
MH  - Humans
MH  - *Receptors, CXCR4
MH  - *HIV Infections/drug therapy
MH  - Chemokine CXCL12
MH  - Inflammation/drug therapy
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Drug Discovery
OTO - NOTNLM
OT  - CXCL12
OT  - CXCR4
OT  - chemokines
OT  - drug discovery
OT  - inflammatory disease
EDAT- 2024/01/05 06:43
MHDA- 2024/04/08 06:42
CRDT- 2024/01/05 01:22
PHST- 2023/11/25 00:00 [revised]
PHST- 2023/10/19 00:00 [received]
PHST- 2023/12/16 00:00 [accepted]
PHST- 2024/04/08 06:42 [medline]
PHST- 2024/01/05 06:43 [pubmed]
PHST- 2024/01/05 01:22 [entrez]
AID - 10.1002/med.22011 [doi]
PST - ppublish
SO  - Med Res Rev. 2024 May;44(3):1189-1220. doi: 10.1002/med.22011. Epub 2024 Jan 4.